Incorporating novel strategies, such as targeting the cGAS-STING pathway, alongside established therapies like mesalazine, could pave the way for more effective and less invasive approaches to CAC prevention in high-risk IBD populations, complementing existing surveillance programs. Here, CGAS is linked to inflammatory bowel disease.